AZD6793

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Type 2 Diabetes MellitusChronic Obstructive Pulmonary Disease (COPD)

150 competitors in Type 2 Diabetes Mellitus

#DrugCompanyPhaseTrials

1

DWP16001

Daewoong Pharmaceutical Co. LTD.

Phase 3

52

Retatrutide

Eli Lilly

Phase 3

13

Elecoglipron

AstraZeneca

Phase 3

54

Ganagliflozin

HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Phase 3

15

Imeglimin

PPoxel SA

Phase 3

16

Dorzagliatin

HHua Medicine Limited

Phase 3

—7

Adenocard

Astellas

Preclinical

18

NOVOLIN R

Novo Nordisk

Preclinical

19

Dostinex

Pfizer

Preclinical

—10

Golytely

Bayer

Preclinical

—Show 35 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Tics2 trials

A Study to Investigate the Safety and Pharmacokinetics of AZD6793 in Healthy Japanese and Chinese Participants

Completed·AstraZeneca·Phase 1·NCT06368440·39 enrolled

A Study to Assess the Pharmacokinetics of AZD6793 When Administered Alone and in Combination With Itraconazole in Healthy Participants.

Completed·AstraZeneca·Phase 1·NCT06494644·17 enrolled

Chronic Obstructive Pulmonary Disease1 trial

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oral AZD6793 in Healthy and Chronic Obstructive Pulmonary Disease Participants, to Assess the Relative Oral Bioavailability Between Two Formulations, and the Food Effect on the PK of AZD6793 Compared to Fasting State.

Completed·AstraZeneca·Phase 1·NCT05662033·93 enrolled

Type 2 Diabetes Mellitus1 trial

A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With Type 2 Diabetes Mellitus

Recruiting·AstraZeneca·Phase 1·NCT07433062·28 enrolled

Chronic Obstructive Pulmonary Disease (COPD)1 trial

A Multicentre, Parallel-group, Phase IIb, Randomised, Double-blind, Placebo-controlled, 3-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO)

Recruiting·AstraZeneca·Phase 2·NCT07082738·987 enrolled

Details

Drug Info

Related News